Columbus Evan Weese Columbus Evan Weese

Columbus AR startup raises $2 million pre-seed round

Three former employees of renowned augmented reality (AR) company Magic Leap have raised $2 million to build their own AR business in Columbus. Greg Tran, Martin Smith, and Sean Couture unveiled their company, Trace, by announcing an oversubscribed $2 million pre-seed, co-led by Rev1 Ventures and Impellent Ventures.

Read More
Columbus Evan Weese Columbus Evan Weese

Intel’s 10 biggest projects around the world—including in Ohio 

In Ohio, construction is well underway on Intel’s newest U.S. site in more than 40 years, the company said while sharing an update of progress at its 10 biggest projects around the world. Around the world throughout 2023, Intel used 145,000 tons of steel and poured more than 2 million cubic yards of concrete—32X more than for New York’s Empire State Building—to construct and expand its new facilities.

Read More
Columbus Evan Weese Columbus Evan Weese

Root Co-Founder and former colleague launch next venture with $7 million Seed Round

Columbus-based RWX has raised a $7 million seed round and launched Mint, a Continuous Integration and Continuous Deployment (CI/CD) platform. RWX was founded by Tommy Graves and Dan Manges, who was the CTO of Root, a technology-powered car insurance carrier, which he co-founded in 2015 and took public in 2020 via an IPO. Graves was a senior engineering manager at Root.

Read More
Columbus Evan Weese Columbus Evan Weese

Drive Capital announces $750 million strategic investment, new minority owner

Columbus-based Drive Capital has announced a strategic investment of at least $750 million in future fund commitments while also selling a minority stake in its management company. Drive says the commitment by Collective Global and Collective Global Asset Owners will advance its ability to invest in world-class technology companies across its target market in the “Driveway”, a $12 trillion region in North America between the Hudson River and the Rocky Mountains.

Read More
Columbus Evan Weese Columbus Evan Weese

What to know about Columbus’ red hot BioTech industry

With a string of major fundraising announcements, product developments, and new facility debuts, Columbus is shaping into a force in the biotechnology space. In fact, it’s among the nation’s fastest-growing biotech hubs, says Eddie Pauline, president and CEO of Ohio Life Sciences, a trade group for biotech, pharmaceutical, gene therapy, and academic organizations.

Read More
Columbus Evan Weese Columbus Evan Weese

Columbus-based Redi Health raises $14 million for digital pharma support

Redi Health, a Columbus-based provider of digital pharma support to patients with chronic health conditions, has raised $14 million in a Series B round. Redi bridges the gap between consumer technology and clinical health and support, engaging patients with medication reminders, symptom management, diet and nutrition advice, weight and activity tracking, and health literacy and education.

Read More
Columbus Evan Weese Columbus Evan Weese

Ohio State sets record with $1.5 billion in R&D Funding

The Ohio State University’s annual R&D expenditures reached an all-time record of $1.449 billion last year, the university disclosed in its annual report of resources available to perform cutting-edge science and creative expression research. The total represents a 6% increase over FY 2022.

Read More
Columbus Evan Weese Columbus Evan Weese

Nationwide Children’s Hospital, Ohio State leading first-of-its-kind pediatric device consortium

Several of Ohio’s biggest names in healthcare are teaming up for a first-of-its-kind partnership to produce and commercialize pediatric medical devices. With support from a $6.95 million grant from the Food and Drug Administration (FDA), Nationwide Children’s Hospital and The Ohio State University are leading the Midwest Pediatric Device Consortium - the first of its kind in the Midwest.

Read More
Columbus Ohio Tech News Columbus Ohio Tech News

Columbus BioTech, Clarametyx Biosciences, raises $33 million Series A

Clarametyx Biosciences, a Columbus-based BioTech startup, has raised a $33 million Series A round to advance its cutting-edge anti-biofilm biologics for combating serious bacterial infections. The company, founded in 2020, specializes in developing targeted, immune-empowering biologic therapies to address persistent infections linked to biofilms.

Read More

Get Ohio tech news straight to your inbox.